Dr. Chelsea Gawryletz, MD
Claim this profileSt Joseph Hospital
Studies Breast Cancer
Studies Skin Cancer
7 reported clinical trials
19 drugs studied
Area of expertise
1Breast Cancer
HER2 positive
ER positive
Stage IV
2Skin Cancer
Stage IV
HER2 positive
ER positive
Affiliated Hospitals
Clinical Trials Chelsea Gawryletz, MD is currently running
Tisotumab Vedotin
for Cancer
This trial will study tisotumab vedotin to find out whether it is an effective treatment alone or with other anticancer drugs for certain solid tumors and what side effects (unwanted effects) may occur. There are seven parts to this study. * In Part A, the treatment will be given to participants every 3 weeks (3-week cycles). * In Part B, participants will receive tisotumab vedotin on Days 1, 8, and 15 every 4-week cycle. * In Part C, participants will receive tisotumab vedotin on Days 1 and 15 of every 4-week cycle. * In Part D, participants will be given treatment on Day 1 of every 3-week cycle. Participants in Part D will get tisotumab vedotin with either: * Pembrolizumab or, * Pembrolizumab and carboplatin, or * Pembrolizumab and cisplatin * In Part E, participants will receive tisotumab vedotin on Days 1 and 15 of every 4-week cycle. * In Part F, participants will receive tisotumab vedotin on Days 1, 15, and 29 of every 6-week cycle. Participants in Part F will get tisotumab vedotin with pembrolizumab. * In Part G, participants will receive tisotumab vedotin on Days 1, 15, and 29 of every 6-week cycle. Participants in Part G will get tisotumab vedotin with pembrolizumab and carboplatin.
Recruiting1 award Phase 216 criteria
Alpelisib + Tucatinib
for Breast Cancer
This trial tests a combination of two drugs, tucatinib and alpelisib, in patients with a specific type of advanced breast cancer. These patients have a genetic mutation and a type of cancer that may not respond well to standard treatments. The drugs work by blocking signals that help cancer cells grow. Alpelisib is approved for treating certain types of advanced breast cancer.
Recruiting1 award Phase 1 & 211 criteria
More about Chelsea Gawryletz, MD
Clinical Trial Related6 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Chelsea Gawryletz, MD has experience with
- Tucatinib
- Abemaciclib
- Anastrozole
- Exemestane
- Imlunestrant
- Letrozole
Breakdown of trials Chelsea Gawryletz, MD has run
Breast Cancer
Skin Cancer
Breast cancer
Gastroesophageal Junction Adenocarcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Chelsea Gawryletz, MD specialize in?
Chelsea Gawryletz, MD focuses on Breast Cancer and Skin Cancer. In particular, much of their work with Breast Cancer has involved HER2 positive patients, or patients who are ER positive.
Is Chelsea Gawryletz, MD currently recruiting for clinical trials?
Yes, Chelsea Gawryletz, MD is currently recruiting for 4 clinical trials in Denver Colorado. If you're interested in participating, you should apply.
Are there any treatments that Chelsea Gawryletz, MD has studied deeply?
Yes, Chelsea Gawryletz, MD has studied treatments such as Tucatinib, Abemaciclib, Anastrozole.
What is the best way to schedule an appointment with Chelsea Gawryletz, MD?
Apply for one of the trials that Chelsea Gawryletz, MD is conducting.
What is the office address of Chelsea Gawryletz, MD?
The office of Chelsea Gawryletz, MD is located at: St Joseph Hospital, Denver, Colorado 80218 United States. This is the address for their practice at the St Joseph Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.